Terns Pharmaceuticals

Yahoo Finance • 8 days ago

2 Under-the-Radar Stocks That Could Soar

Key Points Terns Pharmaceuticals and Rhythm Pharmaceuticals are developing weight loss medicines. Terns Pharmaceuticals has an upcoming data readout for a promising oral candidate. Rhythm Pharmaceuticals is targeting label expansions for... Full story

Yahoo Finance • 15 days ago

SA Asks: Which biotechs could be acquired by year's end?

[word m and a made with wood building blocks, stock image] Maksim Labkouski The fourth quarter has historically been a busy time for the biopharma industry, with the sector generally seeing a significant uptick in M&A activity. We asked... Full story

Yahoo Finance • last month

Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025

FOSTER CITY, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story

Yahoo Finance • 2 months ago

Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered significant attention from analysts and inv... Full story

Yahoo Finance • 2 months ago

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ... Full story

Yahoo Finance • 2 months ago

Terns (TERN) Q2 Net Loss Narrows 16%

Key Points Net loss per share for Q2 2025 was $(0.26). No revenue reported as Terns remains a clinical-stage, pre-commercial biotech. A strong cash position of $315.4 million as of Q2 2025 is expected to fund operations into 2028.These 10... Full story

Yahoo Finance • 3 months ago

Terns pharmaceuticals CEO Burroughs buys $90k in shares

Amy L. Burroughs, Chief Executive Officer of Terns Pharmaceuticals , Inc. (NASDAQ:TERN), recently purchased 23,314 shares of the company’s common stock at a price of $3.8702 per share. The transaction, which occurred on June 25, 2025, amo... Full story

Yahoo Finance • 3 months ago

Terns completes enrollment in Phase 2 obesity drug trial

FOSTER CITY, Calif. - Terns Pharmaceuticals, Inc. (NASDAQ:TERN), a $321 million market cap biotech company currently trading below its InvestingPro Fair Value, has completed enrollment in its Phase 2 FALCON clinical trial of TERN-601, an o... Full story

Yahoo Finance • 3 months ago

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024 Phase 2 FALCON clinical trial of TERN-601 completed enrollment; 12-week data expected in 4Q 2025 FOSTER... Full story

Yahoo Finance • 3 months ago

Citizens JMP reiterates Terns Pharmaceuticals stock rating on positive data

Citizens JMP analyst Silvan Tuerkcan reiterated a Market Outperform rating and $20.00 price target on Terns Pharmaceuticals (NASDAQ:TERN), a $350 million market cap biotech company. According to InvestingPro data, analysts’ targets range... Full story

Yahoo Finance • 4 months ago

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addres... Full story

Yahoo Finance • 5 months ago

Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addres... Full story

Yahoo Finance • 6 months ago

Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addr... Full story

Yahoo Finance • 6 months ago

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity w... Full story

Yahoo Finance • 7 months ago

Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference

TERN-701 CARDINAL study progressing well; dose expansion expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 New TERN-701 data from ongoing U.S. healthy volunteer PK study shows improved drug-drug interaction pro... Full story

Yahoo Finance • 7 months ago

Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer

FOSTER CITY, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story

Yahoo Finance • 7 months ago

Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors

FOSTER CITY, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story

Yahoo Finance • 8 months ago

Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story

Yahoo Finance • 8 months ago

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story

Yahoo Finance • 2 years ago

Terns Pharmaceuticals to Present at the JMP Securities Hematology and Oncology Summit

FOSTER CITY, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to addre... Full story